- Home
- MMC vs GILD Comparison
MMC vs GILD Comparison
Compare MMC & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMC
- GILD
- Stock Information
- Founded
- MMC 1871
- GILD 1987
- Country
- MMC United States
- GILD United States
- Employees
- MMC N/A
- GILD N/A
- Industry
- MMC Specialty Insurers
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MMC Finance
- GILD Health Care
- Exchange
- MMC Nasdaq
- GILD Nasdaq
- Market Cap
- MMC 104.0B
- GILD 119.7B
- IPO Year
- MMC N/A
- GILD 1992
- Fundamental
- Price
- MMC $230.04
- GILD $109.95
- Analyst Decision
- MMC Hold
- GILD Buy
- Analyst Count
- MMC 16
- GILD 27
- Target Price
- MMC $231.19
- GILD $101.88
- AVG Volume (30 Days)
- MMC 2.1M
- GILD 7.6M
- Earning Date
- MMC 04-17-2025
- GILD 02-11-2025
- Dividend Yield
- MMC 1.42%
- GILD 2.87%
- EPS Growth
- MMC 8.63
- GILD N/A
- EPS
- MMC 8.18
- GILD 0.38
- Revenue
- MMC $24,458,000,000.00
- GILD $28,754,000,000.00
- Revenue This Year
- MMC $11.02
- GILD $0.82
- Revenue Next Year
- MMC $5.94
- GILD $3.21
- P/E Ratio
- MMC $28.11
- GILD $289.34
- Revenue Growth
- MMC 7.57
- GILD 6.04
- 52 Week Low
- MMC $196.17
- GILD $62.07
- 52 Week High
- MMC $235.50
- GILD $111.03
- Technical
- Relative Strength Index (RSI)
- MMC 64.22
- GILD 75.82
- Support Level
- MMC $228.30
- GILD $94.56
- Resistance Level
- MMC $231.72
- GILD $106.69
- Average True Range (ATR)
- MMC 2.95
- GILD 2.29
- MACD
- MMC 0.33
- GILD 1.15
- Stochastic Oscillator
- MMC 89.58
- GILD 93.47
About MMC Marsh & McLennan Companies Inc.
Marsh McLennan is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (a management and economic consultancy). About half of its revenue is generated outside the US.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).